Warning on transmissible Agents
This guideline provides standard texts for warning statements on transmissible agents to be included, in summary of product characteristics (SmPCs) and package leaflets for plasma-derived medicinal products. The original guideline (CPMP/BPWG/BWP/561/03) was adopted by CHMP in October 2003 and came into operation in May 2004. This revision affects only the introduction, where an update related to vCJD and an addition concerning albumin as excipient are now included.
Here you will get more information: "Guideline on the warning on transmissible agents in summary of product characteristics (SmPCs) and package leaflets for plasma-derived medicinal products".
Related GMP News
05.09.2024Revision of USP Chapter <1033> on Validation of Biological Assays published
05.09.2024Next Generation of Genome Editing?
05.09.2024A further Step for the SoHO Regulation
05.09.2024FDA Developments on Biosimilars
21.08.2024Update of the Overview of upcoming CBER Guidelines in 2024
29.05.2024New FDA Draft Guideline regarding the Use of Human- and Animal-derived Materials